 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SCG101 / SCG Cell Therapy
Journal: Genetically redirected HBV-specific T cells target HBsAg-positive hepatocytes and primary lesions in HBV-associated HCC. (Pubmed Central) - May 29, 2024
P1
Transferred T cells expanded, developed a stem cell-like memory phenotype, and were still detectable after six months in the patient's blood. SCG101 T-cell therapy showed encouraging efficacy and safety in pre-clinical models and in a patient with primary HBV-HCC and concomitant chronic hepatitis B with the capability to eliminate HBsAg+ cells and achieve sustained tumor control after single dosing.
- SCG101 / SCG Cell Therapy
First-in-human clinical result of a novel HBV-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma (HCC) (Poster Area) - Apr 29, 2024 - Abstract #EASLILC2024EASL_ILC_2716;
- SCG101 / SCG Cell Therapy
First-in-human trial of novel HBsAg-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1024;
The persistence of TCR+ T cells, reduction of serum HBsAg, and tumor response are strongly correlated with the mechanism of action of SCG101. A phase I/II clinical trial to further evaluate the safety and efficacy of SCG101 is ongoing.
- SCG101 / SCG Cell Therapy
Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma. (Available On Demand; Poster Bd # 497a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1306;
P1, P1/2
Autologous SCG101 T cell therapy may provide a new treatment option for patients with advanced Hepatitis B virus-related HCC. Clinical trial information: NCT05417932.
- | SCG101 / SCG Cell Therapy
Trial initiation date: TCR-T: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 8, 2022
P1/2, N=46, Recruiting, Sponsor: SCG Cell Therapy Pte. Ltd.
Clinical trial information: NCT05417932. Initiation date: Jul 2022 --> Oct 2022
- SCG101 / SCG Cell Therapy
Enhanced anti-tumor activity of HBsAg specific TCR-T (SCG101) in hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) by preventing T cell exhaustion through PD-1/PD-L1 axis blockade (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_683;
Procedures used in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at WuXi AppTec (Nantong) Co., Ltd. IACUC serial number: ON01-QD009-2020.
- || SCG101 / SCG Cell Therapy
Enrollment open: TCR-T: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 20, 2022
P1/2, N=46, Recruiting, Sponsor: SCG Cell Therapy Pte. Ltd.
IACUC serial number: ON01-QD009-2020. Not yet recruiting --> Recruiting
- | SCG101 / SCG Cell Therapy
New P1/2 trial: TCR-T: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 14, 2022
P1/2, N=46, Not yet recruiting, Sponsor: SCG Cell Therapy Pte. Ltd.
- SCG101 / SCG Cell Therapy
Antiviral and antitumor activity of SCG101, an autologous HBV-specific T cell receptor engineered T cell (TCR-T) therapy in HBV-related advanced hepatocellular carcinoma (HCC) patients after receiving ≥ 2 prior lines of systemic therapies (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1817;
Early and sustained HBsAg reduction demonstrates encouraging antiviral activity with target engagement of SCG101 and might serve as a potential predictive marker of antitumor efficacy. Preliminary data support further systematic clinical evaluation.
- | SCG101 / SCG Cell Therapy
New P1 trial, Metastases: Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC (clinicaltrials.gov) - Apr 20, 2022
P1, N=36, Recruiting, Sponsor: Peking Union Medical College Hospital